WO2007015999A2 - Process for synthesizing a substituted pyrazole - Google Patents

Process for synthesizing a substituted pyrazole Download PDF

Info

Publication number
WO2007015999A2
WO2007015999A2 PCT/US2006/028545 US2006028545W WO2007015999A2 WO 2007015999 A2 WO2007015999 A2 WO 2007015999A2 US 2006028545 W US2006028545 W US 2006028545W WO 2007015999 A2 WO2007015999 A2 WO 2007015999A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
produce
ester
reacting
Prior art date
Application number
PCT/US2006/028545
Other languages
French (fr)
Other versions
WO2007015999A3 (en
Inventor
Lushi Tan
James Christopher Mcwilliams
Frederick W. Hartner
Naoki Yoshikawa
Wenji Li
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to EP06800239A priority Critical patent/EP1910303A2/en
Priority to CA002614537A priority patent/CA2614537A1/en
Priority to JP2008524008A priority patent/JP2009502923A/en
Priority to US11/988,849 priority patent/US7709658B2/en
Priority to AU2006276072A priority patent/AU2006276072A1/en
Publication of WO2007015999A2 publication Critical patent/WO2007015999A2/en
Publication of WO2007015999A3 publication Critical patent/WO2007015999A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/02—Preparation of hydrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00—Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04—Preparation of hydrazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates

Definitions

  • the present invention relates to a process for synthesizing a substituted pyrazole.
  • the compound is particularly useful as an anti-diabetic compound.
  • the compound has demonstrated activity as a glucagon receptor antagonist.
  • Glucagon serves as the major regulatory hormone attenuating the effect of insulin in its inhibition of liver gluconeogenesis and is normally secreted by ⁇ -cells in pancreatic islets in response to falling blood glucose levels.
  • the hormone binds to specific receptors in liver cells that triggers glycogenolysis and an increase in gluconeogenesis through cAMP-mediated events. These responses generate glucose (e.g. hepatic glucose production) to help maintain euglycemia by preventing blood glucose levels from falling significantly.
  • type II diabetics In addition to elevated levels of circulating insulin, type II diabetics have elevated levels of plasma glucagon and increased rates of hepatic glucose production.
  • One object of the present invention is to provide a process wherein the protecting groups are easily removed without resort to harsh deprotection conditions.
  • Another object of the present invention is to provide a process which facilitates selective deprotection.
  • the present invention involves a process of synthesizing a compound of formula I:
  • a pharmaceutically acceptable salt or solvate thereof comprising reacting a compound of formula IE: with 1,1 '-carbonyldiimidazole and a beta alanine ester or a salt or solvate thereof, and hydrolyzing with a base to pOrovide a compound of formula I.
  • Ph 2 -Fc-P-(IBu) 2 is a Josiphos ligand which is disclosed in U. S. Pat. No. 6,777,567B2 (Solvias) and commercially available from Strem.
  • Xyl-P-Phos is disclosed in U.S. Pat No. 5,886,182 (Synetix) and commercially available from Strem.
  • Me-f-Ketal phos is similarly commercially available from Chiral Quest.
  • Rh based catalysts may be used as well.
  • the compound described herein may be prepared according to the methodology outlined in the following general synthetic schemes.
  • R 1 represents a suitable ester forming group.
  • Examples include C 1-I0 alkyl, such as ethyl, isopropyl, t-butyl, t-butylcyclohexyl and the like, and benzyl. Preferred is ethyl.
  • Prot Gp-hydrazine refers to a protected hydrazine, protected with a suitable protecting group, designated Prot Gp, which represents the protecting group.
  • suitable protecting group designated Prot Gp, which represents the protecting group. Examples include t-butoxycarbonyl, methoxycarbonyl, carboxybenzoyl, benzyl and the like.
  • Ketone A is condensed with a protected hydrazine to produce a protected hydrazone B.
  • This condensation reaction is conducted in a suitable solvent, such as toluene, under acidic conditions, with for example, acetic acid, at about 60 degrees C.
  • the protected hydrazone B is asymmetrically hydrogenated using a hydrogen source, such as hydrogen gas, and a catalyst to produce a chiral N-protected-hydrazine C.
  • This hydrazine is produced in enantiomeric excess (approximately 86%ee).
  • a suitable catalyst for this conversion is a precatalyst, such as Rh(COD)BF 4 mixed with a suitable ligand, such as Josiphos.
  • Deprotection of the protecting group in C and subsequent enantiomeric excess upgrade using benzene sulfonic acid in ethanol provides a crystalline hydrazine D as the benzenesulfonate salt (not shown), with greater than 99% enantiomeric excess.
  • the 1 ,3-dione G is prepared by condensation of ester E and ketone F in the presence of a base, such as potassium t-butoxide. Cyclization between D and G can then be undertaken in a suitable solvent, such as DMAc, NMP and the like, in the presence of an additive.
  • suitable solvent such as DMAc, NMP and the like
  • additives include LiCl, LiBr, MgBr 2 and other Lewis acids. Alternatively, tetrabutyl ammonium chloride can be used.
  • the additive provides high regioselectivity, as high as about 17:1.
  • the ester forming moiety of compound // is thereafter hydrolyzed with a suitable base, for example, NaOH, to produce acid ///.
  • acid III can then be combined with a beta alanine ester, or a salt or solvate thereof, preferably the HCl salt, to form the beta alanyl ester of ///(not shown).
  • This ester may then be hydrolyzed, such as with additional base, for example, NaOH, and optionally crystallized, such as from acetonitrile and water, to produce the title compound /as a free acid.
  • 3,5-dichlorophenylacetylene J is produced by displacing bromine from bromo- 3,5-dichlorobenzene H. Such reactions are typically conducted under an inert atmosphere, in base, e.g., triethylamine in a suitable solvent.
  • This intermediate is reacted with 6-methoxy-2-naphthoic acid chloride K to produce an acetylenic ketone L.
  • the acetylenic ketone L is thereafter reacted with the chiral hydrazine D to produce the chiral intermediate //.
  • Compound // is thereafter incorporated into the synthesis described above with respect to Scheme 3, reacting with a beta alanyl ester and then hydrolyzing to produce the target compound /.
  • the daily dosage range for the compound of formula I is within the general range of from about 0.001 mg to about 1000 mg, in single or divided doses. It may be necessary to use dosages outside of these limits in some cases. Representative dosages for adults thus range from about 0.1 mg to about 1.0 g per day, preferably about 1 mg to about 200 mg, in single or divided doses.
  • compositions comprise a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier encompasses a product comprising the active compound and one or more inert ingredient(s), (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from the combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions between ingredients.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present application relates to a process for the synthesis of the compound of formula 1. The compound of formula I is a glucagon receptor antagonist and is useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.

Description

TITLE OF THE INVENTION
PROCESS FOR SYNTHESIZING A SUBSTITUTED PYRAZOLE
BACKGROUND OF THE INVENTION The present invention relates to a process for synthesizing a substituted pyrazole. The compound is particularly useful as an anti-diabetic compound. In particular, the compound has demonstrated activity as a glucagon receptor antagonist.
Glucagon serves as the major regulatory hormone attenuating the effect of insulin in its inhibition of liver gluconeogenesis and is normally secreted by α-cells in pancreatic islets in response to falling blood glucose levels. The hormone binds to specific receptors in liver cells that triggers glycogenolysis and an increase in gluconeogenesis through cAMP-mediated events. These responses generate glucose (e.g. hepatic glucose production) to help maintain euglycemia by preventing blood glucose levels from falling significantly.
In addition to elevated levels of circulating insulin, type II diabetics have elevated levels of plasma glucagon and increased rates of hepatic glucose production. The compound that is the subject of the process described herein in an antagonist of glucagon, and thus useful in improving insulin responsiveness in the liver, decreasing the rate of gluconeogenesis and lowering the rate of hepatic glucose output resulting in a decrease in the levels of plasma glucose.
One object of the present invention is to provide a process wherein the protecting groups are easily removed without resort to harsh deprotection conditions.
Another object of the present invention is to provide a process which facilitates selective deprotection.
These and other objects will be apparent from the teachings contained herein.
SUMMARY OF THE INVENTION
The present invention involves a process of synthesizing a compound of formula I:
Figure imgf000002_0001
or a pharmaceutically acceptable salt or solvate thereof, comprising reacting a compound of formula IE:
Figure imgf000003_0001
with 1,1 '-carbonyldiimidazole and a beta alanine ester or a salt or solvate thereof, and hydrolyzing with a base to pOrovide a compound of formula I.
DETAILED DESCRIPTION OF THE INVENTION
The invention is described in connection with the following abbreviatons and definitions.
Figure imgf000003_0003
Ph2-Fc-P-CtBu)2 Xyl-P-Phos Me-f-Ketalphos
Figure imgf000003_0002
- 2 - Ph2-Fc-P-(IBu)2 is a Josiphos ligand which is disclosed in U. S. Pat. No. 6,777,567B2 (Solvias) and commercially available from Strem. Xyl-P-Phos is disclosed in U.S. Pat No. 5,886,182 (Synetix) and commercially available from Strem. Me-f-Ketal phos is similarly commercially available from Chiral Quest. A variety of Rh based catalysts may be used as well.
The compound described herein may be prepared according to the methodology outlined in the following general synthetic schemes.
SCHEME I
Figure imgf000004_0001
SCHEME 2
Figure imgf000004_0002
Figure imgf000004_0003
SCHEME 3
Figure imgf000005_0001
Within the schemes above, R1 represents a suitable ester forming group. Examples include C1-I0 alkyl, such as ethyl, isopropyl, t-butyl, t-butylcyclohexyl and the like, and benzyl. Preferred is ethyl.
Similarly, the notation Prot Gp-hydrazine refers to a protected hydrazine, protected with a suitable protecting group, designated Prot Gp, which represents the protecting group. Examples include t-butoxycarbonyl, methoxycarbonyl, carboxybenzoyl, benzyl and the like.
Many of the intermediates contain an asymmetric center and thus occur as racemates and mixtures thereof. The present invention therefore includes all such isomeric forms of the compounds, in pure form as well as in mixtures.
The process described herein is generally considered a stereospecifϊc synthesis. Ketone A is condensed with a protected hydrazine to produce a protected hydrazone B. This condensation reaction is conducted in a suitable solvent, such as toluene, under acidic conditions, with for example, acetic acid, at about 60 degrees C.
The protected hydrazone B is asymmetrically hydrogenated using a hydrogen source, such as hydrogen gas, and a catalyst to produce a chiral N-protected-hydrazine C. This hydrazine is produced in enantiomeric excess (approximately 86%ee). A suitable catalyst for this conversion is a precatalyst, such as Rh(COD)BF4 mixed with a suitable ligand, such as Josiphos. Deprotection of the protecting group in C and subsequent enantiomeric excess upgrade using benzene sulfonic acid in ethanol provides a crystalline hydrazine D as the benzenesulfonate salt (not shown), with greater than 99% enantiomeric excess.
With reference to Scheme 2, the 1 ,3-dione G is prepared by condensation of ester E and ketone F in the presence of a base, such as potassium t-butoxide. Cyclization between D and G can then be undertaken in a suitable solvent, such as DMAc, NMP and the like, in the presence of an additive. Suitable examples of additives include LiCl, LiBr, MgBr2 and other Lewis acids. Alternatively, tetrabutyl ammonium chloride can be used. The additive provides high regioselectivity, as high as about 17:1. The ester forming moiety of compound // is thereafter hydrolyzed with a suitable base, for example, NaOH, to produce acid ///. As shown with reference to Scheme 3, acid III can then be combined with a beta alanine ester, or a salt or solvate thereof, preferably the HCl salt, to form the beta alanyl ester of ///(not shown). This ester may then be hydrolyzed, such as with additional base, for example, NaOH, and optionally crystallized, such as from acetonitrile and water, to produce the title compound /as a free acid.
An alternative process for the synthesis of compounds of formula II is shown below in Scheme 4.
Scheme 4
Figure imgf000006_0001
K
II
D
Briefly, 3,5-dichlorophenylacetylene J is produced by displacing bromine from bromo- 3,5-dichlorobenzene H. Such reactions are typically conducted under an inert atmosphere, in base, e.g., triethylamine in a suitable solvent. This intermediate is reacted with 6-methoxy-2-naphthoic acid chloride K to produce an acetylenic ketone L. The acetylenic ketone L is thereafter reacted with the chiral hydrazine D to produce the chiral intermediate //. Compound // is thereafter incorporated into the synthesis described above with respect to Scheme 3, reacting with a beta alanyl ester and then hydrolyzing to produce the target compound /.
Dose Ranges
The daily dosage range for the compound of formula I is within the general range of from about 0.001 mg to about 1000 mg, in single or divided doses. It may be necessary to use dosages outside of these limits in some cases. Representative dosages for adults thus range from about 0.1 mg to about 1.0 g per day, preferably about 1 mg to about 200 mg, in single or divided doses.
Pharmaceutical Compositions Pharmaceutical compositions comprise a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier. This encompasses a product comprising the active compound and one or more inert ingredient(s), (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from the combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions between ingredients.
While the invention has been described and illustrated with reference to specific embodiments, numerous changes, modifications, and substitutions can be made therein without departing from the spirit and scope of the invention. It is intended therefore that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

Claims

WHAT IS CLAIMED IS:
1. A process for the synthesis of a compound of formula /:
Figure imgf000008_0001
comprising reacting a compound of formula ///:
Figure imgf000008_0002
in the presence of l,r-carbonyldiimidazole with an ester of beta-alanine or a salt or solvate thereof to produce an ester of formula II, and hydrolyzing with a base to provide a compound of formula /.
2. A process for the synthesis of a compound of formula C:
Figure imgf000008_0003
comprising reacting a compound of formula B:
Figure imgf000008_0004
wherein R1 represents an ester forming group with a catalyst and a hydrogen source to produce a compound of formula C.
3. A process for the synthesis of a compound of formula II:
Figure imgf000009_0001
wherein R1 represents an ester forming group, comprising reacting a compound of formula G:
Figure imgf000009_0002
and a compound of formula D:
Figure imgf000009_0003
to produce a compound of formula II.
4. A process for the synthesis of a compound of formula /:
Figure imgf000009_0004
comprising:
(a) reacting compounds of formulas E and F:
Figure imgf000010_0001
E and
in the presence of potassium ϊ-butoxide to produce a compound of formula G:
Figure imgf000010_0002
(b) reacting compound G with a compound of formula D:
Figure imgf000010_0003
wherein R1 represents an ester forming group, to produce a compound of formula IL
Figure imgf000010_0004
(c) hydrolyzing the ester of compound II with a base to produce a compound of formula IH:
Figure imgf000010_0005
(d) reacting compound ///with a beta alanine ester or a salt or solvate thereof to produce a beta alanyl ester of IH, and
(e) hydrolyzing the beta alanyl ester of III to produce a compound of formula I.
PCT/US2006/028545 2005-07-26 2006-07-21 Process for synthesizing a substituted pyrazole WO2007015999A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06800239A EP1910303A2 (en) 2005-07-26 2006-07-21 Process for synthesizing a substituted pyrazole
CA002614537A CA2614537A1 (en) 2005-07-26 2006-07-21 Process for synthesizing a substituted pyrazole
JP2008524008A JP2009502923A (en) 2005-07-26 2006-07-21 Method for the synthesis of substituted pyrazoles
US11/988,849 US7709658B2 (en) 2005-07-26 2006-07-21 Process for synthesizing a substituted pyrazole
AU2006276072A AU2006276072A1 (en) 2005-07-26 2006-07-21 Process for synthesizing a substituted pyrazole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70245405P 2005-07-26 2005-07-26
US60/702,454 2005-07-26

Publications (2)

Publication Number Publication Date
WO2007015999A2 true WO2007015999A2 (en) 2007-02-08
WO2007015999A3 WO2007015999A3 (en) 2007-06-28

Family

ID=37460179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028545 WO2007015999A2 (en) 2005-07-26 2006-07-21 Process for synthesizing a substituted pyrazole

Country Status (7)

Country Link
US (1) US7709658B2 (en)
EP (1) EP1910303A2 (en)
JP (1) JP2009502923A (en)
CN (1) CN101300232A (en)
AU (1) AU2006276072A1 (en)
CA (1) CA2614537A1 (en)
WO (1) WO2007015999A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
DE102008057718A1 (en) 2008-11-17 2010-05-20 Skw Stickstoffwerke Piesteritz Gmbh Regioselective preparation of N-(1H-pyrazolyl methyl)amide compounds, useful e.g. as nitrification inhibitors, comprises reacting hydrazine methyl carboxylic acid amide compounds with 1,3-dicarbonyl compounds
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
US8710236B2 (en) 2007-02-09 2014-04-29 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
EP2799428A2 (en) 2008-08-13 2014-11-05 Metabasis Therapeutics, Inc. Glucagon antagonists
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
CN106279023A (en) * 2015-05-12 2017-01-04 中国科学院上海药物研究所 3,4,5-tri-substituted pyrazolecarboxylic compounds, preparation method, pharmaceutical composition and purposes
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
US11077092B2 (en) 2012-12-10 2021-08-03 Merck Sharp & Dohme Corp. Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346830B1 (en) * 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8361959B2 (en) * 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
TW201811752A (en) * 2016-09-06 2018-04-01 比利時商健生藥品公司 Indazole derivatives useful as glucagon receptor antagonists
TWI757332B (en) * 2016-09-06 2022-03-11 比利時商健生藥品公司 Indazole derivatives useful as glucagon receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
WO2004069158A2 (en) * 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
WO2005121097A2 (en) * 2004-06-04 2005-12-22 Merck & Co., Inc. Pyrazole derivatives, compositions containing such compounds and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
EP0948257A4 (en) 1996-11-20 1999-12-29 Merck & Co Inc Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JP2001504489A (en) 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド Triaryl-substituted imidazoles and methods of use
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ES2304797T3 (en) 1997-12-19 2008-10-16 Amgen Inc. PIRIDINE AND PIRIDAZINE SUBSTITUTED COMPOUNDS AND THEIR PHARMACEUTICAL USE.
EP1113801A4 (en) 1998-09-17 2002-10-02 Bristol Myers Squibb Co METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION
CN1356977A (en) 1999-05-17 2002-07-03 诺沃挪第克公司 Glucagon antagonists/inverse agonists
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
CZ20024105A3 (en) 2000-06-23 2003-05-14 Novo Nordisk A/S Glucagon antagonists/inversion agonists
EP1305285B1 (en) 2000-07-25 2007-05-16 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
WO2003048109A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
MXPA04007474A (en) 2002-02-01 2004-11-10 Dainippon Pharmaceutical Co 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same.
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
AU2003249296A1 (en) 2002-07-19 2004-02-09 Baxter Healthcare S.A. Systems and methods for performing peritoneal dialysis
AU2003298889A1 (en) 2002-12-04 2004-06-23 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
US20040248937A1 (en) 2003-04-14 2004-12-09 The Institute For Pharmaceutical Discovery Llc Substituted phenylalkanoic acids for the treatment of diabetes
AU2004238240A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
AR056574A1 (en) 2005-10-19 2007-10-10 Merck & Co Inc PIRAZOL DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE PROCEDURES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
WO2004069158A2 (en) * 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
WO2005121097A2 (en) * 2004-06-04 2005-12-22 Merck & Co., Inc. Pyrazole derivatives, compositions containing such compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M.J. BURK ET AL: TETRAHEDRON, vol. 50, no. 15, 1994, pages 4399-4428, XP002129547 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169201B2 (en) 2007-02-09 2015-10-27 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US10807946B2 (en) 2007-02-09 2020-10-20 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US10239829B2 (en) 2007-02-09 2019-03-26 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US9701626B2 (en) 2007-02-09 2017-07-11 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US8710236B2 (en) 2007-02-09 2014-04-29 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
US8232413B2 (en) 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
US9783494B2 (en) 2008-08-13 2017-10-10 Metabasis Therapeutics, Inc. Glucagon antagonists
EP2799428A2 (en) 2008-08-13 2014-11-05 Metabasis Therapeutics, Inc. Glucagon antagonists
US8907103B2 (en) 2008-08-13 2014-12-09 Metabasis Therapeutics, Inc. Glucagon antagonists
US11352321B2 (en) 2008-08-13 2022-06-07 Metabasis Therapeutics, Inc. Glucagon antagonists
US10221130B2 (en) 2008-08-13 2019-03-05 Metabasis Therapeutics, Inc. Glucagon antagonists
DE102008057718A1 (en) 2008-11-17 2010-05-20 Skw Stickstoffwerke Piesteritz Gmbh Regioselective preparation of N-(1H-pyrazolyl methyl)amide compounds, useful e.g. as nitrification inhibitors, comprises reacting hydrazine methyl carboxylic acid amide compounds with 1,3-dicarbonyl compounds
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US9056834B2 (en) 2010-12-23 2015-06-16 Pfizer Inc. Glucagon receptor modulators
US8809342B2 (en) 2010-12-23 2014-08-19 Pfizer Inc. Glucagon receptor modulators
US8933104B2 (en) 2010-12-23 2015-01-13 Pfizer Inc. Glucagon receptor modulators
US8507533B2 (en) 2011-02-08 2013-08-13 Pfizer Inc. Glucagon receptor modulators
US9073871B2 (en) 2011-02-08 2015-07-07 Pfizer Inc. Glucagon receptor modulators
US8859591B2 (en) 2011-02-08 2014-10-14 Pfizer Inc. Glucagon receptor modulators
US9452999B2 (en) 2011-02-08 2016-09-27 Pfizer Inc. Glucagon receptor modulators
US9139538B2 (en) 2011-07-22 2015-09-22 Pfizer Inc. Quinolinyl glucagon receptor modulators
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
US11077092B2 (en) 2012-12-10 2021-08-03 Merck Sharp & Dohme Corp. Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106279023A (en) * 2015-05-12 2017-01-04 中国科学院上海药物研究所 3,4,5-tri-substituted pyrazolecarboxylic compounds, preparation method, pharmaceutical composition and purposes
CN106279023B (en) * 2015-05-12 2021-06-22 中国科学院上海药物研究所 3,4, 5-trisubstituted pyrazole compound, preparation method, pharmaceutical composition and application
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists

Also Published As

Publication number Publication date
CN101300232A (en) 2008-11-05
CA2614537A1 (en) 2007-02-08
US7709658B2 (en) 2010-05-04
EP1910303A2 (en) 2008-04-16
JP2009502923A (en) 2009-01-29
AU2006276072A1 (en) 2007-02-08
US20090054662A1 (en) 2009-02-26
WO2007015999A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
EP1910303A2 (en) Process for synthesizing a substituted pyrazole
EP0656354B1 (en) Substituted N-piperidino 3-pyrazolecarboxamide
FR2741621A1 (en) NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO2007085718A1 (en) Sulfonamide derivatives, preparation thereof and therapeutic use thereof
EP0658546A1 (en) Novel 3-pyrazolecarboxamide derivatives with cannabinoid receptor affinity
JPH10502354A (en) Phosphodiesterase IV inhibitory compounds and methods of inhibition
ZA200504719B (en) 1-alkyl-3-aminodazoles
CA2696237C (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
LU85245A1 (en) NOVEL AZOLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIFUNGALS AND FUNGICIDES
US9850267B2 (en) Crystalline fosaprepitant dicyclohexylamine salt and its preparation
JPH05140063A (en) Dipeptide derivative and medicine for preventing and improving osteopathy, containing the same compound as active component
JPH0232268B2 (en)
WO2002060880A1 (en) Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
EP1421065A1 (en) Hydrazinopeptoids and their uses for treating cancers
JPS61100565A (en) Indoleacetic acid derivative
JP4725939B2 (en) Method for producing 1-alkyl-pyrazole-5-carboxylic acid ester III
EP0151052B1 (en) Aminoethylimidazole, pharmaceutical composition containing them and process for their preparation
JP4222206B2 (en) Method for producing aminostilbene derivative
Hsu et al. (1, 3‐Diphenyl‐1H‐Pyrazol‐4‐yl)‐Methylamine Analogues as Inhibitors of Dipeptidyl Peptidases
WO1991008201A1 (en) (hetero) 4-arylmethoxy phenyl diazole derivatives, method for preparing same, and their therapeutical applications
EP0445116A1 (en) [(aryl-4-piperazinyl-1)-2 ethoxy]-3 p-cymene, the ortho, meta and para derivatives mono- or disubstituted on the phenyl nucleus of said product, process for preparing said derivatives, and drugs containing said compounds as active ingredients
JP2540391B2 (en) Process for producing β-ketoester
JPH0454668B2 (en)
JP2022028990A (en) Production method for amide alcohol compound
FR2575470A1 (en) Amino derivatives of N-imidazolylmethyl-diphenylazomethines, a process for preparing them and their therapeutic application.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680027223.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2614537

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11988849

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006276072

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 609/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008524008

Country of ref document: JP

Ref document number: 2006800239

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006276072

Country of ref document: AU

Date of ref document: 20060721

Kind code of ref document: A